Drug Updates

Glenmark Pharmaceuticals dispatches Rufinamide Tablets USP, 200 mg and 400 mg

Glenmark Pharmaceuticals Limited (Glenmark) has sent off Rufinamide Tablets USP, 200 mg and 400 mg, a restorative likeness Banzel®1 Tablets, 200 mg and 400 mg of Eisai, Inc. Glenmark was one of the primary ANDA candidates to present a significantly complete ANDA for Rufinamide Tablets USP, 200 mg and 400 mg, with a passage IV accreditation and got last endorsement on May 16, 2016.

Glenmark’s present portfolio comprises of 172 items approved for appropriation in the U.S. commercial center and 45 ANDA’s forthcoming endorsement with the U.S. FDA. Notwithstanding these inner filings, Glenmark proceeds to distinguish and investigate outer advancement organizations to enhance and speed up the development of its current pipeline and portfolio.

Author

Leave a Reply

Your email address will not be published. Required fields are marked *